Leukemia Research
Volume 27, Issue 5 , Pages 413-423 , May 2003

Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype

  • Eloisi C Lopes

      Affiliations

    • Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) IDEHU-CONICET, Junin 956 4 piso, Buenos Aires 1113, Argentina
    • Corresponding Author InformationCorresponding author. Tel.: +54-11-4964-8259x108; fax: +54-11-4964-0024.
    • Fellow from UBA.
    • ,
  • Mariana Garcia

      Affiliations

    • Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) IDEHU-CONICET, Junin 956 4 piso, Buenos Aires 1113, Argentina
    • Fellow from UBA.
    • ,
  • Fernando Benavides

      Affiliations

    • Science Park-Research Division, M.D. Anderson Cancer Center, The University of Texas, Smithville, TX 78957, USA
    • ,
  • Jianjun Shen

      Affiliations

    • Science Park-Research Division, M.D. Anderson Cancer Center, The University of Texas, Smithville, TX 78957, USA
    • ,
  • Claudio J Conti

      Affiliations

    • Science Park-Research Division, M.D. Anderson Cancer Center, The University of Texas, Smithville, TX 78957, USA
    • ,
  • Elida Alvarez

      Affiliations

    • Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) IDEHU-CONICET, Junin 956 4 piso, Buenos Aires 1113, Argentina
    • Members of the National Research Career (CONICET).
    • ,
  • Silvia E Hajos

      Affiliations

    • Department of Immunology, School of Pharmacy and Biochemistry, University of Buenos Aires (UBA) IDEHU-CONICET, Junin 956 4 piso, Buenos Aires 1113, Argentina
    • Members of the National Research Career (CONICET).

Received 11 June 2002 ,Accepted 4 September 2002.

References 

  1. Siva AC, Fernandes SR, Stephen AG, Femina MJ, Scheper RJ, Kickhoefer VA, et al.  Up-regulation of vaults may be necessary but not sufficient for multidrug resistance. Int. J. Cancer. 2001;92:195–202
  2. D’Hondt V, Symann M, Machiels JP. Chemoprotection and selection by chemotherapy of multidrug resistance-associated protein-1 (MRP1) transduced cells. Curr. Gene Ther. 2001;1:359–366
  3. Johnson DR, Finch RA, Lin ZP, Zeiss CJ, Sartorelli AC. The pharmacological phenotype of combined multidrug-resistance mdr1a/1b- and mrp1-deficient mice. Cancer Res. 2001;61:1469–1476
  4. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of AT dependent transporters. Nat. Rev. Cancer. 2002;2:48–58
  5. Chan HSL, Lu Y, Grogan TM, Haddad G, Hipfner DR, Cole SPC, et al.  Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of p-glycoprotein. Cancer Res. 1997;57:2325–2330
  6. Theis JG, Liau-Chu M, Chan HS, Doyle J, Greenberg ML, Koren G. Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. J. Clin. Oncol. 1995;13:2508–2516
  7. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, et al.  Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood. 1999;93:787–795
  8. Naito M, Watanabe T, Tsuge H, Koyama T, Oh-hara T, Tsuruo T. Potentiation of the reversal activity of SDZ PSC 833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int. J. Cancer. 1996;67:435–440
  9. Reed JC, Miyashit T, Takayama S, Wang HG, Sato T, Krajewski S, et al.  Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance therapy. J. Cell Biochem. 1996;60:23–32
  10. Malorni W, Rainaldi G, Tritarelli E, Rivabene R, Cianfriglia M, Lehnert M, et al.  Tumor necrosis factor α is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P-170 glycoprotein. Int. J. Cancer. 1996;67:238–247
  11. Kaufman D, Chabner BA. Clinical strategies for cancer treatment: the role of drugs. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice, 2nd ed. Philadelphia, PA: Lippincott-Raven; 1996. p. 1–16.
  12. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. 2000;65:95–106
  13. Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, et al.  Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int. J. Cancer. 1999;82:860–867
  14. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia. 1999;13:1854–1858
  15. Lopes EC, Scolnik M, Alvarez E, Hajos SE. Cytotoxic effect of cyclosporin-A and PSC 833 in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells. Leukemia Res. 2001;25:85–93
  16. Lugasi H, Hajos SE, Murphy JR, Strom TB, Nichols J, Penarroja C, et al.  Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor-a model for human T-cell malignancies expressing IL-2 receptor. Int. J. Cancer. 1990;45:163–167
  17. Lopes EC, Ernst G, Aulicino P, Vanzulli S, Garcı́a M, Alvarez E, et al.  Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia. Clin. Exp. Metastasis. 2002;19:283–290
  18. Sanchez LM, Gravisaco MJ, Mongini C, Waldner C, Alvarez E, Hajos SE. Alternative exon-specific PCR method for the analysis of human CD44 isoform expression. Oncol. Rep. 1999;6:219–224
  19. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry. 1990;29:10351–10356
  20. Kang YK, Zhan Z, Regis J, Robey R, Meadows B, Dickstein B, et al.  Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood. 1995;86:1515–1524
  21. Lopes EC, Garcı́a M, Vellón L, Alvarez E, Hajos SE. Correlation between decreased apoptosis and multidrug resistance (MDR) in murine leukemic T cell lines. Leukemia Lymphoma. 2001;42:775–787
  22. Shen J, Bao Y, Liu HM, Lee P, Leonard JV, Chen YT. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J. Clin. Invest. 1996;98:352–357
  23. Huang Y, Ibrado AM, Reed JC, Bullock G, Ray S, Tang C, et al.  Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia. 1997;11:253–257
  24. Tang-Wai DF, Kajiji S, DiCapua F, Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry. 1995;34:32–39
  25. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood. 1993;82:1288–1299
  26. Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui CH, Campana D. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood. 1998;91:1001–1007

PII: S0145-2126(02)00216-3

doi: 10.1016/S0145-2126(02)00216-3

Leukemia Research
Volume 27, Issue 5 , Pages 413-423 , May 2003

Article Tools

* Image Usage & Resolution